LMNL - Liminal shares slide after plans to stop fezagepras development

Liminal BioSciences (LMNL) announces that it has decided to stop its plans to move fezagepras into a Phase II study in Idiopathic Pulmonary Fibrosis and a phase Ia/IIb study in Hypertriglyceridemia, following interim pharmacokinetic ("PK") results.Shares down nearly 12% post market.The company is continuing to evaluate the interim PK results.Once the study is complete, the company expects that a full analysis of the complete PK data set from the phase 1 study will help determine the choice of any other potential indications for further development of fezagepras.Liminal highlighted that no dose-limiting adverse events or other potential safety signals have been observed in the study to date.

For further details see:

Liminal shares slide after plans to stop fezagepras development